Sandra Lynn Snyder, PA

Sandra Snyder practices at Bayshore Pathology in Port Charlotte, Florida.

Sandra Snyder's NPI, 1053300723, was assigned on October 17, 2005. Sandra Snyder holds Florida license PA9101056.

Sandra Snyder's primary practice is Bayshore Pathology, at 18338 Murdock Cir Ste 101, Port Charlotte, FL 33948. The practice phone is (941) 313-9009.

Sandra Snyder's primary practice is Bayshore Pathology in Port Charlotte, Florida. The medical group on file is Dermatology Group of Florida. Dmand AI also links Sandra Snyder to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sandra Snyder practices, 3 sites in all. Vendor and product names are available with a free account.

Medical is Sandra Snyder's primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Sandra Snyder is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Sandra Snyder is licensed in Florida.

Dmand AI lists acne, acute skin infection, ankle or foot injury, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, itchy rashes and psoriasis among the conditions Sandra Snyder treats.

CMS data shows 1,657 Medicare services from Sandra Snyder across 13 procedure codes in 2024, for 383 Medicare patients. Medicare paid $62,170 for them. Every service was in an office.

CMS counts 383 Medicare patients who saw Sandra Snyder in 2024. The largest group is 65 to 74, with 213 patients. 75% of them have high cholesterol, and 70% have high blood pressure. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Sandra Snyder's median patient age at 61, with 56% women.

In 2024, Sandra Snyder wrote 1,157 Medicare Part D claims for 511 patients. 86% of them were for generic drugs. CMS names the drug for 992 of them, across 22 drugs with 11 or more claims each, at $600,123 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Sandra Snyder for performance year 2024, reported individually. Sandra Snyder accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 397 general payments to Sandra Snyder from 34 drug and device companies from 2024 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Janssen Pharmaceuticals, Inc paid the most, $21,917.